Saul Kivimae

Company: Nektar Therapeutics

Job title: Vice President & Head of Pharmacology

Seminars:

Assessing Novel Therapeutically Active Anti-TNFR2 Agonistic Antibodies in Promoting Treg Proliferation and the Induction of Treg Functional Markers 11:30 am

Illuminating the unique properties of TNFR2 agonism for Treg targeted therapies Optimizing TNFR2 targeting on Tregs with novel approaches Showcasing preclinical data from Nektar’s differentiated TNFR2 agonistRead more

day: Day 1 Treg Modulators track AM

Industry Leader’s Fireside Chat: Comparing Treg Cell Therapies & Treg Modulators as Effective Treatments for Inflammatory & Autoimmune Diseases 8:30 am

Exploring the effectiveness of treatment personalization to direct the future of Treg therapies Discussing technological challenges in Treg cell therapy or Treg modulator development Comparing Treg cell therapy and modulator treatment efficacy to identify enhancements to progress Treg therapiesRead more

day: Conference Day One AM